73756-39-5

Usage

Uses

Used in Pharmaceutical Industry:
2-tetradecyloctadecanoic acid is used as a bioactive compound for its potential therapeutic applications in the treatment of obesity, diabetes, and cardiovascular diseases. It modulates lipid metabolism and has potential anti-inflammatory and antidiabetic properties, making it a promising candidate for the development of new drugs and therapies.
Used in Nutritional Supplements:
2-TDO can be used as a nutritional supplement to support healthy lipid metabolism and promote overall health. Its potential benefits in energy metabolism, insulin sensitivity, and inflammation may contribute to improved metabolic health and well-being.
Used in Cosmetics and Personal Care Products:
Due to its unique chemical structure and potential health benefits, 2-tetradecyloctadecanoic acid can be incorporated into cosmetics and personal care products as an ingredient with potential anti-inflammatory and skin health-promoting properties.
Used in Research and Development:
2-TDO is used as a subject of research in the fields of biology, biochemistry, and pharmacology. Its potential role in various biological processes and therapeutic applications makes it an important compound for further investigation and development of new treatments and products.

InChI:InChI=1/C32H64O2/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-31(32(33)34)29-27-25-23-21-19-16-14-12-10-8-6-4-2/h31H,3-30H2,1-2H3,(H,33,34)

Upstream product

• 32582-32-4 2-tetradecyl-octadecanol 
• 54580-47-1 diethyl 2-tetradecylmalonate 
• 112-82-3 hexadecanyl bromide 
• 19218-94-1 1-iodotetradecane 
• 57-11-4 stearic acid 
• 36653-82-4 1-Hexadecanol 

Downstream Products

• 1416474-30-0 C₁₁₈H₁₈₂O₁₃ 

Relevant academic research and scientific papers

Tris(2-aminoethyl)amine-based α-branched fatty acid amides - Synthesis of lipids and comparative study of transfection efficiency of their lipid formulations This article is dedicated to Professor Gerald Brezesinski on occasion of his 65th birthday.

The synthesis of a new class of cationic lipids, tris(2-aminoethyl)amine-based α-branched fatty acid amides, is described resulting in a series of lipids with specific variations in the lipophilic as well as the hydrophilic part of the lipids. In-vitro structure/transfection relationships were established by application of complexes of these lipids with plasmid DNA (pDNA) to different cell lines. The α-branched fatty acid amide bearing two tetradecyl chains and two lysine molecules (T14diLys) in mixture with the co-lipid 1,2-di-[(9Z)-octadec-9-enoyl]-sn-glycero-3-phosphoethanolamine (DOPE) (1/2, n/n) exhibits effective pDNA transfer in three different cell lines, namely Hep-G2, A549, and COS-7. The presence of 10% serum during lipoplex incubation of the cells did not affect the transfection efficiency. Based on that, detailed investigations of the complexation of pDNA with the lipid formulation T14diLys/DOPE 1/2 (n/n) were carried out with respect to particle size and charge using dynamic light scattering (DLS), ζ-potential measurements, and transmission electron microscopy (TEM). Additionally, the lipoplex uptake was investigated by confocal laser scanning microscopy (CLSM). Overall, lipoplexes prepared from T14diLys/DOPE 1/2 (n/n) offer large potential as lipid-based polynucleotide carriers and further justify advanced examinations.

Bithiophene sulfonamide-based molecular and polymeric semiconductors

The present invention relates to new semiconducting compounds having at least one optionally substituted bithiophene sulfonamide moiety. The compounds disclosed herein can exhibit high carrier mobility and/or efficient light absorption/emission characteristics, and can possess certain processing advantages such as solution-processability and/or good stability at ambient conditions.

Development of vizantin, a safe immunostimulant, based on the structure-activity relationship of trehalose-6,6′-dicorynomycolate

Vizantin, 6,6′-bis-O-(3-nonyldodecanoyl)-α,α′- trehalose, was developed as a safe immunostimulator on the basis of a structure-activity relationship (SAR) study with trehalose 6,6′- dicorynomycolate (TDCM). It was possible to synthesize vizantin on a large scale more easily than in the case of TDCM, and the compound exhibited more potent prophylactic effect on experimental lung metastasis of B16-F0 melanoma cells. Because vizantin stimulated human macrophages, it is a promising candidate for clinical application.